FDA Clears Way for Denovo to Launch Phase 3 Trial of DB102 for DLBCL Patients in US
News
The U.S. Food and Drug Administration (FDA) has given Denovo Biopharma the green light to advance its investigational drug DB102 into a Phase 3 clinical trial for diffuse large B-cell lymphoma ... Read more
ADC Therapeutics Raises $200M to Fund Two Lead Programs in Non-Hodgkin’s Lymphoma
News
ADC Therapeutics, a company specializing in the development of antibody drug conjugates (ADCs) for several cancer indications, has raised $200 million through a private placement. The financing will be used ... Read more
Cancer Patient Gets Visit From Miley Cyrus and Liam Hemsworth
Pre-treatment with CD37 Antibody Enhances Amount of Betalutin to NHL Tumors, Study Finds
News
Preliminary trial results show that pre-treatment with the antibody lilotomab may increase the amount of Nordic Nanovector‘s investigational therapy Betalutin that reaches tumor lesions in patients with non-Hodgkin’s lymphoma (NHL). Representatives from ... Read more
The Science of Depression
Immune Design’s G100 Receives EMA’s Orphan Drug Designation for Follicular Non-Hodgkin’s Lymphoma
News
The European Medicines Agency (EMA) has granted G100 orphan drug status for the treatment of follicular non-Hodgkin’s lymphoma, Immune Design, the drug’s developer, announced in a press release. The EMA orphan drug designation – ... Read more
French Researchers Develop Quick, Cost-Effective Test to Detect DLBCL Subtypes
News
A newly developed assay can rapidly and accurately recognize different subtypes of diffuse large B-cell lymphoma (DLBCL), providing useful diagnostic information that could help doctors match tumors with the right ... Read more
The Importance of Self-Care When You’re Battling Cancer
Researchers Identify Enzyme as New Target for Treating Classical Hodgkin’s Lymphoma
News
An enzyme called monoamine oxidase-A (MAO-A) contributes to the growth of classical Hodgkin’s lymphoma cells but not other lymphoma cells, a study reports. It also indicated that a combination of ... Read more
FDA Approves Yescarta, First CAR T-cell Therapy for Lymphoma
News
The U.S. Food and Drug Administration (FDA) approved Kite Pharma‘s Yescarta (axicabtagene ciloleucel) for the treatment of relapsed or refractory large B-cell lymphoma patients who received at least two prior ... Read more
